Want to see HK:1276 full AI Analyst Report?
Top Page
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
(1276)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$55.00
▲(18.28% Upside)
Action:Upgraded
Date:10/29/26
The score is driven primarily by excellent financial performance—high margins, very low leverage, and strong operating cash flow. Offsetting this are a premium valuation (high P/E and low yield) and a mixed technical picture, with longer-term moving averages still pointing to a downtrend despite improving shorter-term levels.
Positive Factors
High Profitability
Exceptional gross and net margins indicate strong economics across the company’s pharmaceutical portfolio. This profitability provides resources for research, clinical development, commercialization, and market expansion while offering resilience against moderate cost or pricing pressure over the next several quarters.
Negative Factors
Volatile Free-Cash-Flow Conversion
Although operating cash generation is strong, free-cash-flow conversion has been uneven and was negative in 2022. Periodic working-capital swings or investment cycles can make cash available for reinvestment less predictable than accounting earnings over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
Exceptional gross and net margins indicate strong economics across the company’s pharmaceutical portfolio. This profitability provides resources for research, clinical development, commercialization, and market expansion while offering resilience against moderate cost or pricing pressure over the next several quarters.
Read all positive factors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$376.11B
Dividend Yield0.45%
Average Volume (3M)4.70M
Price to Earnings (P/E)36.0
Beta (1Y)0.47
Revenue Growth11.35%
EPS Growth21.43%
CountryHK
Employees20,602
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.53
Shares Outstanding258,197,600
10 Day Avg. Volume5,396,076
30 Day Avg. Volume4,695,147
Financial Highlights & Ratios
PEG Ratio2.21
Price to Book (P/B)6.79
Price to Sales (P/S)13.15
P/FCF Ratio50.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$80.14Price Target Upside72.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.63
Revenue Forecast (FY)HK$39.32B
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncolo...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
94
Very Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.36B | 35.19B | 29.77B | 25.26B | 24.23B | 31.02B |
| Gross Profit | 32.11B | 30.33B | 25.68B | 21.36B | 20.26B | 26.20B |
| EBITDA | 10.90B | 10.63B | 8.46B | 5.95B | 5.19B | 5.19B |
| Net Income | 10.12B | 8.58B | 6.74B | 4.76B | 4.45B | 5.46B |
Balance Sheet | ||||||
| Total Assets | 89.78B | 77.73B | 53.33B | 48.21B | 47.57B | 48.03B |
| Cash, Cash Equivalents and Short-Term Investments | 50.97B | 45.69B | 26.69B | 22.95B | 20.06B | 22.90B |
| Total Debt | 493.42M | 48.18M | 73.44M | 692.54M | 1.91B | 1.36B |
| Total Liabilities | 10.98B | 8.98B | 4.30B | 2.99B | 4.31B | 4.38B |
| Stockholders Equity | 78.19B | 68.17B | 48.42B | 44.55B | 42.47B | 42.82B |
Cash Flow | ||||||
| Free Cash Flow | 7.08B | 9.20B | 5.80B | 6.82B | -827.89M | 3.39B |
| Operating Cash Flow | 11.56B | 12.50B | 7.90B | 8.46B | 1.44B | 5.40B |
| Investing Cash Flow | -5.36B | -3.05B | -2.03B | 1.35B | 444.51M | -559.25M |
| Financing Cash Flow | -1.31B | 8.66B | -1.65B | -3.48B | -363.05M | -1.62B |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Technical Analysis
Positive
46.50
Price Trends
47.23
Positive
51.91
Negative
59.30
Negative
Market Momentum
0.21
Negative
57.83
Neutral
58.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1276, the sentiment is Positive. The current price of 46.5 is below the 20-day moving average (MA) of 48.23, below the 50-day MA of 47.23, and below the 200-day MA of 59.30, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 57.83 is Neutral, neither overbought nor oversold. The STOCH value of 58.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1276.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$200.60B | 25.54 | 18.26% | 1.47% | 24.97% | 43.23% | |
71 Outperform | HK$376.11B | 36.01 | 13.87% | 0.45% | 11.35% | 21.43% | |
66 Neutral | HK$326.45B | 62.26 | 14.22% | ― | 34.73% | ― | |
63 Neutral | HK$86.36B | 30.96 | 7.56% | 2.47% | 14.57% | -31.09% | |
63 Neutral | HK$142.55B | 97.86 | 6.06% | ― | 42.64% | 9.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$78.59B | -68.16 | -10.86% | ― | 42.47% | -15.80% |
* Healthcare Sector Average
HK:1276
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
50.65
-24.29
-32.41%
HK:1177
Sino Biopharmaceutical
4.85
-2.05
-29.71%
HK:1801
Innovent Biologics
81.60
-5.40
-6.21%
HK:9926
Akeso, Inc.
83.50
-29.90
-26.37%
HK:3692
Hansoh Pharmaceutical Group Company Limited
33.08
-2.05
-5.84%
HK:6160
BeOne Medicines Ltd
222.20
36.40
19.59%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Corporate Events
Hengrui Pharma Wins NMPA Nod for ICU Use of Innovative Sedative
Oct 27, 2026
Jiangsu Hengrui Pharmaceuticals has received approval from China’s National Medical Products Administration for an additional indication of its Class 1 innovative drug, Remimazolam Tosilate for Injection. The sedative has now been cleared fo...
Hengrui Pharma Posts Strong Profit Surge in Q3 2026
Oct 27, 2026
Jiangsu Hengrui Pharmaceuticals has released its unaudited third-quarter report for the period ended 30 September 2026, prepared under PRC Accounting Standards and published in both Chinese and English. The board and senior management formally aff...
Jiangsu Hengrui sets board meeting to approve nine‑month results
Oct 14, 2026
Jiangsu Hengrui Pharmaceuticals has scheduled a board meeting for October 27, 2026 to review and approve the quarterly results for the nine months ended September 30, 2026 for the company and its subsidiaries. The approval and subsequent publicati...
Hengrui Pharma Seals Up to US$2.6 Billion Global Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Drug
Sep 29, 2026
Jiangsu Hengrui Pharmaceuticals has signed a license agreement with Novo Nordisk A/S for HRS-1596, its independently developed GLP-1/GIP dual receptor agonist with potential once-weekly oral dosing, aimed at obesity, type 2 diabetes and other meta...
Hengrui Pharma Clears All Resolutions at 2026 Extraordinary Shareholders’ Meeting
Sep 24, 2026
Jiangsu Hengrui Pharmaceuticals reported that all resolutions at its first extraordinary shareholders’ meeting of 2026, held on September 24 in Shanghai, were approved by poll, with the board of directors and the board secretary in full atte...
Hengrui Wins NMPA Approval for New Uses of Innovative Thrombocytopenia Drug
Sep 10, 2026
Jiangsu Hengrui Pharmaceuticals has received approval from China’s National Medical Products Administration for two new indications of its self-developed Class 1 innovative drug, Hetrombopag Olamine Tablets. The approvals cover use in adult ...
Hengrui Pharmaceuticals Calls Extraordinary Meeting on New Share Schemes and Buyback Mandate
Sep 8, 2026
Jiangsu Hengrui Pharmaceuticals has called a first extraordinary shareholders’ meeting for September 24, 2026 in Shanghai to seek approval for new employee stock ownership schemes for its A shares and a new H share scheme. The proposals incl...
Hengrui Pharma Sets September EGM to Approve 2026 H Share Scheme
Sep 7, 2026
Jiangsu Hengrui Pharmaceuticals has scheduled its 2026 first extraordinary shareholders’ meeting for September 24 in Shanghai to seek approval for the proposed 2026 H Share Scheme and other matters. The company will close its H share registe...
Hengrui Pharma Wins NMPA Approval for Innovative PNH Drug
Aug 20, 2026
Jiangsu Hengrui Pharmaceuticals announced that its subsidiary Chengdu Suncadia Medicine has received marketing approval from China’s National Medical Products Administration for Licancopan Fumarate Capsules, a self-developed Class 1 innovati...
Hengrui Pharma Launches RMB1–2 Billion A-Share Buyback for Employee Ownership Plan
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced a plan to repurchase its A shares on the Shanghai Stock Exchange through centralized price bidding, committing no less than RMB1 billion and no more than RMB2 billion of its own funds. The re...
Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals has approved a 2026 A share employee stock ownership scheme, which will take effect upon shareholder approval and will use existing A shares rather than issuing new equity or options. The programme aims to align the...
Jiangsu Hengrui Proposes 2026 H Share Incentive Scheme to Strengthen Governance
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals has proposed a new 2026 H Share Scheme that will grant restricted share units to directors, senior management and key personnel, subject to approval at an extraordinary shareholders’ meeting. The scheme is des...
Jiangsu Hengrui Pharmaceuticals Announces Resignation of Joint Company Secretary
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that joint company secretary Ms. Liu Xiaohan resigned with effect from August 19, 2026, with no disagreement with the board or issues requiring shareholder attention. Following her departure, the...
Jiangsu Hengrui Publishes Unaudited Interim Results for First Half of 2026
Aug 19, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd., a Hong Kong-listed Chinese drug maker, specializes in developing and marketing pharmaceutical products for a broad healthcare market. The company operates as a regulated joint stock enterprise with a dive...
Hengrui Pharma Wins NMPA Nod for New Autoimmune Indication of Innovative Drug
Aug 6, 2026
Jiangsu Hengrui Pharmaceuticals has received approval from China’s National Medical Products Administration for a new indication of its self-developed Class 1 innovative drug, Ivarmacitinib Sulfate Tablets (SHR0302). The tablet, a 4 mg presc...
Hengrui Wins First-in-China Anti-HER2 Approval for Colorectal Cancer
Aug 6, 2026
Jiangsu Hengrui Pharmaceuticals has announced that its subsidiary Suzhou Suncadia Biopharmaceuticals received Chinese regulatory approval for a new indication of trastuzumab rezetecan for injection, classified as a Class 2.2 therapeutic biological...
Jiangsu Hengrui Board to Review Interim Results and Dividend in August
Aug 6, 2026
Jiangsu Hengrui Pharmaceuticals has scheduled a board meeting for August 19, 2026 to review and approve the interim financial results for the first half of 2026. The board will also consider the declaration of an interim dividend for the six month...
Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin Analog
Jul 29, 2026
Jiangsu Hengrui Pharmaceuticals has obtained approval from China’s National Medical Products Administration to market insulin sudelidec injection, a Class 1 therapeutic biological product it independently developed. The drug is China’s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.